Does Medicare Cover Trelegy?

COPD is one of the most common chronic conditions in the Medicare population — decades of smoking, occupational exposures, and aging lungs catch up with millions of older adults — and Trelegy Ellipta has become one of the most prescribed maintenance inhalers for it. So the coverage question comes up constantly: my doctor put me on Trelegy, will Medicare pay for it?

The answer is yes, and unlike the high-cost specialty biologics, Trelegy’s coverage is relatively straightforward. The main things to understand are its tier placement, the realistic out-of-pocket cost, and a couple of restrictions that show up on some plans.

What Trelegy is

Trelegy Ellipta is a once-daily maintenance inhaler that combines three medications in a single device:

• An inhaled corticosteroid (fluticasone furoate) to reduce airway inflammation
• A long-acting muscarinic antagonist (umeclidinium) to relax airway muscles
• A long-acting beta-agonist (vilanterol) to keep airways open

This “triple therapy” in one inhaler is convenient — one device, once a day — and is used for both COPD and asthma. It’s a maintenance medication, meant to be taken daily to prevent flare-ups, not a rescue inhaler for acute symptoms.

How Medicare covers it

Trelegy is a self-administered inhaled medication, so it’s covered under Medicare Part D (the prescription drug benefit), not Part B. Every standalone Part D plan and most Medicare Advantage plans with drug coverage include it on the formulary, typically on Tier 3 — the preferred brand tier.

That tier placement is good news relative to specialty drugs. Tier 3 means a moderate copay or coinsurance rather than the steep specialty-tier coinsurance that drugs like Dupixent carry.

What you’ll pay in 2026

Trelegy’s wholesale price runs around $650 per month. Your actual cost depends on where you are in the Part D benefit:

• Deductible phase: If your plan has a deductible (up to $590 in 2026), you pay the negotiated price until it’s met — roughly one month’s cost gets you most of the way there.
• After the deductible: You pay your Tier 3 cost-sharing — often a $40–$100 copay or about 25% coinsurance, depending on the plan.
• The $2,000 cap: Once your total out-of-pocket on covered Part D drugs reaches $2,000 in the calendar year, you pay $0 for the rest of the year.

For someone whose main prescription is Trelegy, the yearly cost usually lands well under the $2,000 cap. For someone taking Trelegy plus other brand or specialty drugs, the combined total is what counts toward the cap — and once you hit it, everything is $0.

Two ways to lower the cost:

• Use your plan’s preferred pharmacy — Tier 3 drugs are often $10–$30 cheaper per fill at preferred pharmacies.
• Ask about 90-day supplies through mail order, which many plans discount for maintenance medications.

Why there’s no generic

Trelegy is a brand-only drug, which is why it sits on a brand tier rather than a cheap generic tier. The reason is the device: Trelegy combines three specific medications in a patented Ellipta inhaler, and that combination-plus-device is protected, so there’s no generic or direct substitute yet.

If the cost is a strain, it’s worth a conversation with your doctor about alternatives. Depending on your condition, separate inhalers, a two-in-one combination inhaler, or a different triple-therapy product might work as well for you and land on a lower tier. This is a clinical decision — don’t switch on your own — but it’s a reasonable question to raise.

Prior authorization and step therapy

Coverage restrictions vary by plan:

• COPD: Trelegy is often covered without prior authorization, since triple therapy is a standard COPD treatment.
• Asthma: Some plans apply step therapy, asking you to try a simpler combination inhaler first, because asthma guidelines often escalate from two-drug to three-drug therapy.

If your plan requires prior authorization or step therapy, your prescriber documents your diagnosis and prior inhaler use to satisfy it. Check your plan’s formulary (search “Trelegy” or “fluticasone/umeclidinium/vilanterol”) to see the tier and any restriction flags before your first fill.

The bigger COPD coverage picture

Trelegy is usually one piece of a broader COPD or asthma care plan, and Medicare covers the rest of it too:

• Rescue inhalers (albuterol) — Part D, usually a low tier
• Other maintenance inhalers and nebulizer medications — Part D
• Nebulizer equipment — Part B durable medical equipment (20% coinsurance)
• Oxygen therapy, if needed — Part B DME
• Pulmonary rehabilitation — covered under Part B for qualifying COPD patients
• Doctor and specialist visits — Part B

For the newer biologic add-on therapies used in severe eosinophilic COPD, Dupixent is now FDA-approved and covered under Part D as well — relevant if Trelegy alone isn’t controlling your symptoms.

Bottom line

Medicare Part D covers Trelegy Ellipta for both COPD and asthma, typically on the preferred brand tier with a moderate copay, and the $2,000 annual out-of-pocket cap keeps your total yearly cost bounded. It’s a brand-only drug with no generic, so it isn’t cheap, but it’s far more affordable than specialty-tier medications — and using a preferred pharmacy and 90-day fills brings the cost down further. Check your plan’s formulary for tier and prior authorization details, and if cost is a concern, ask your doctor whether a lower-tier inhaler combination would work for your situation.